Skip to main content

Q3/2023 Results

#FutureFresenius continues to provide positive momentum: Fresenius delivers strong third quarter performance and improves operating earnings outlook

  • Application of IFRS 5: Fresenius Group financials for the first time presented excluding Fresenius Medical Care

  • Excellent Group revenue growth of 6% in constant currency to €5.5 billion driven by Operating Companies and Fresenius Vamed

  • Group EBIT increased 10% in constant currency reflecting strong performance of Operating Companies; Fresenius Vamed with operational improvement 

  • Fresenius Kabi with strong organic revenue growth of 7% at top-end of structural growth band; EBIT margin remains within structural band at 14.3%

  • Fresenius Helios with strong organic revenue growth of 5% at top-end of structural growth band despite usual summer effect in Spain 

  • Fresenius Vamed’s transformation progressing 

  • Deconsolidation of Fresenius Medical Care effective by December 2023

  • Divestments advancing: exit of hospital operations in Peru 

  • FY/23 structural productivity savings target of ~€200 million excluding Fresenius Medical Care already achieved in first nine months 

  • Group revenue outlook confirmed, Group EBIT outlook improved

Selected Key Figures Q3/2023


5518 m

+ 6% 1

Q3/22: €5,386 m


519 m

+10% 1

Q3/22: €480 m


648 m


Q3/22: €598 m

1 In constant currency

2 Before special items

Revenue by business segment

€ in millions Q3/23 Q3/22 ChangeGrowth at constant ratesOrganic growthAcquisitionsDivestitures% of total revenue1

Fresenius Kabi


Fresenius Helios


Fresenius Vamed




  • 1 Related to the respective external sales of the business segments. Consolidation effects and corporate entities are not taken into account. Therefore, aggregation to total Group revenue is not possible.